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In vivo expression of podocyte slit diaphragm-associated pro-
teins in nephrotic patients with NPHS2 mutation.
Background. Mutations in NPHS2, encoding podocin, are
a prevalent cause of autosomal-recessive steroid-resistant
nephrotic syndrome (SRNS). Podocin is a protein associated
with the slit diaphragm that interacts with nephrin and CD2-
associated protein (CD2AP) within lipid rafts.
Methods. Using renal biopsies of six patients, we analyzed the
in vivo consequences of different types of NPHS2 mutations on
(1) the podocyte expression and distribution of podocin using
in situ hybridization and immunohistology and (2) the distribu-
tion of related podocyte proteins and glomerular extracellular
matrix components.
Results. In two patients with homozygous 855 856delAA or
419delG mutation, absence of podocyte labeling with the an-
tibodies against the C-terminal domain contrasted with the
normal expression of the N-terminal domain of the protein
along the glomerular basement membrane (GBM). In pa-
tients carrying compound heterozygous mutations or variants
(R168S/467 468insT, R138Q/V180M, and R291W/R229Q),
or single heterozygous 976 977insA, podocin transcription
appeared unchanged but the distribution of the protein was
modified. Podocin was restricted to the podocyte body in the pa-
tient carrying the R168S/467 468insT mutation whereas strong
immunolabeling of the podocyte body was associated with dis-
crete labeling along the GBM in the three others. In all cases,
podocin defect was associated with changes in the distribution
of nephrin, CD2AP, and a-actinin: the proteins were mainly
detected in the podocyte body, with mild expression along the
GBM. There were no detectable changes in the distribution
of other podocyte proteins or glomerular extracellular matrix
components.
Conclusion. NPHS2 mutations result in profound alteration
of podocin expression and/or distribution. Secondary changes in
the distribution of nephrin, CD2AP, and a-actinin are additional
evidences for the scaffolding role of podocin in the organization
of the slit diaphragm.
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Autosomal-recessive steroid-resistant nephrotic syn-
drome (SRNS) associated with NPHS2 mutations, be-
longs to the heterogeneous group of hereditary nephrotic
syndromes [1]. It was initially characterized by child-
hood onset proteinuria, progression to end-stage re-
nal disease (ESRD), absence of recurrence after renal
transplantation, and, at the histologic level, minimal
glomerular changes on early biopsy samples and focal
segmental glomerulosclerosis (FSGS) at later stages [2].
Subsequently, NPHS2 mutations were described in spo-
radic cases of SRNS [3, 4], in late onset FSGS [5], and in
congenital forms of the disease, possibly associated with
NPHS1 heterozygous mutation [6, 7]. Moreover, delayed
recurrence of mild proteinuria, responsive to therapeu-
tic approach, has been observed, after renal transplanta-
tion, in two patients with NPHS2 mutations [8]. NPHS2,
mapped to 1q25–31, is a gene consisting of eight exons [2].
The protein product, a podocyte protein named podocin,
is an integral membrane protein of 383 amino acids, with a
single membrane domain (amino acids 105 to 121) form-
ing a hairpin-like structure placing both N- and C- termi-
nal domains in the cytosol. It belongs to the stomatin
family of lipid-raft–associated proteins [2, 9]. Podocin
plays an important role in the maintenance of the
glomerular filtration barrier as confirmed by the occur-
rence of massive proteinuria and death in the first days
of life in Nphs2−/− mice [10].
By immunoelectron microscopy, using antibodies to
the C- and N- terminal domains of the protein, we and
others previously showed that podocin was located at
the cytoplasmic face of the slit diaphragm [9, 11]. Slit
diaphragms are thin structures connecting interdigitated
podocyte foot processes along the glomerular basement
membrane (GBM). Their existence and structure had
been described 30 years ago, at the ultrastructural level
[12]. But, their importance in the control of glomeru-
lar filtration has been recognized only recently. In ad-
dition to podocin, several other molecules participating
in the formation of slit diaphragms have been identi-
fied through the genetic characterization of hereditary
nephrotic syndrome, or the production of animal models.
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Table 1. Clinical parameters, pathologic, and genetic findings in the six patients with NPHS2 mutations
Mutation
Age at Age at Effect on
Patient onset NS ESRD Nucleotide coding Mutation
Gender years years Renal biopsy I (Age years) II change sequence Exon status
1F 0.5 5.5 MGC (0.6) FSGS (2) 419delG Frameshift 3 Hom
2F 0.4 12 MGC(0.6) FSGS (8) 855 6delAA Frameshift 7 Hom
3M 0.5 7.9 DMP (1.9) 502C→A R168S 4 C Het
467 468insT Frameshift 4
4F 7.5 17 MGC (8.6) 413G→A R138Q 3 C Het
538G→A V180M 5
5F 0.3 9.3 MGC (0.3) 871C →T R291W 7 C Het
686G→A R229Q 5
6F 9 13.7 FSGS (11.9) 976 977insA Frameshift 8 S Het
Abbreviations are: NS, nephrotic syndrome; DMP, diffuse mesangial proliferation; MGC, minimal glomerular changes; FSGS, focal segmental glomerularsclerosis;
Hom, homozygote; C Het, compound heterozygote; S Het, single heterozygous mutation.
Nephrin, a transmembrane cell adhesion molecule of the
immunoglobulin superfamily, is a major component of
the slit diaphragm complex [13–16]. Mutations of the
nephrin gene NPHS1 result in congenital nephrotic syn-
drome of the Finnish type [14] and Nphs1 knock-out mice
have no slit diaphragm and die at birth with massive
proteinuria [17, 18]. Nephrin interacts with podocin and
CD2-associated protein (CD2AP), an adapter protein
that could anchor the nephrin-podocin complex to the
submembranous actin cytoskeleton [9]. The role of
CD2AP in the maintenance of the glomerular filtration
barrier has been demonstrated by the occurrence of con-
genital nephrotic syndrome in CD2AP knockout mice
[19]. In addition, CD2AP haploinsufficiency in humans
may be associated with glomerular disease susceptibility
[20]. P-cadherin and zona occludens-1 (ZO-1) are other
components of the slit diaphragm [21–24]. NEPH1, a
podocyte protein related to, and interacting with nephrin
in the slit diaphragm [25], is important to podocyte func-
tion, since mice lacking NEPH1 develop proteinuria and
perinatal lethality [26]. FAT, a protocadherin is also in-
volved in the maintenance of the glomerular filtration
barrier as shown by the occurrence of nephrotic syn-
drome in mFAT1-deficient mice [27, 28]. No mutation
of the corresponding genes has been found so far in
nephrotic patients. Conversely, mutations in ACTN4, the
gene encoding a-actinin-4, an actin-binding protein lo-
calized in podocyte foot processes, causes an autosomal-
dominant form of FSGS in humans [29] and mice [30]
whereas a-actinin-4 null mice have severe glomerular
disease [31].
In order to determine if and how NPHS2 mutations af-
fect the podocyte phenotype, we analyzed the podocyte
expression of podocin and related proteins in the kid-
neys of six patients suffering from SRNS and in which
NPHS2 mutations have been characterized. We also ex-
amined whether the glomerular distribution of extracel-
lular matrix components was modified in these nephrotic
patients.
METHODS
Patients and kidney tissue specimens
Renal tissue from six patients (three biopsies and three
nephrectomies performed at the time of transplantation)
were available for this study (Table 1). The six patients
had early onset SRNS progressing to ESRD between the
ages of 5.5 and 17 years. Patients 1 and 2 carried homozy-
gous NPHS2 deletions resulting in a frameshift. Data on
podocin expression in patient 1 have been previously
shown [11]. Patient 3 had two different mutations, one
missense and one frameshift. Patient 4 had a compound
missense mutation, including R138Q, a recurrent muta-
tion. Patient 5 had one missense mutation R291W and
the common nonneutral R229Q polymorphism. A single
heterozygous frameshift mutation was identified in pa-
tient 6. These mutations are described in other papers
[2, 7].
Initial renal biopsy showed minimal glomerular
changes in four patients (3 months to 8.6 years old),
diffuse mesangial proliferation in one (1.9 years old)
and FSGS in one (11.9 years old). Repeated renal biop-
sies performed in patients 1 and 2 showed the develop-
ment of FSGS. Severe glomerular sclerosis, sparing only
a few glomeruli, was observed in all end-stage kidneys.
In these end-stage kidneys, sections, including preserved
glomeruli, were carefully selected for immunolabeling
and in situ hybridization studies. Four normal kidneys
(from humans aged 1 to 51 years), unsuitable for trans-
plantation because of vascular problems, were used as
controls.
Dubosq-Brazil or formalin–fixed, paraffin-embedded
tissues were used for light and immunoperoxidase studies.
For immunofluorescence, specimens were immediately
snap-frozen in liquid nitrogen using OCT (Tissue-Tek,
Nile, Inc., Eckhart, IN, USA) and stored at −80◦C until
use. Frozen tissue sections were used for the analysis of
the podocyte phenotype and the distribution of glomeru-
lar extracellular matrix components.
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Table 2. Characteristics of antibodies used in the study
Antibodies Specificity Dilution Source
A Anti podocyte proteins
Rabbit anti-podocin P35 Podocin C-terminal 1:1000 Roselli et al [11]
Rabbit anti-podocin P21 Podocin N-terminal 1:50 Roselli et al [11]
Rabbit anti-nephrin Nephrin 1:500 Tryggvason et al [32]
Rabbit anti-CD2AP (H-290) CD2AP 1:50 Santa Cruz Biotechnology, CA
Rabbit anti-ZO-1 ZO-1 1:10 Zymed Laboratories, South San Francisco, CA
Mouse CD49c a3 integrin 1:100 Beckman Coulter, Brea, CA
Mouse anti- b-dystroglycan b-dystroglycan 1:50 Novocastra Laboratories, UK
Mouse mAb 5C11 Glepp1 1:100 Sigma, Saint Louis, MO
Rabbit anti- a-actinin a-actinin 1:100 Biogenex, San, Ramon, CA
Mouse mAb GID4 Synaptopodin 1:10 Progen Biotechnik GMBH, Heidelberg, Germany
Mouse mAb V9 Vimentin 1:100 Beckman Coulter, Brea, CA
B Anti extracellular matrix
Rabbit anti-[a1(IV)2 a2(IV)] Type IV collagen[a1(IV)2 a2(IV)] 1:60 Novotec, Lyon, France
Mouse mAb anti-a1(IV) a1(IV)NC1 1:2 Wieslab AB, Lund, Sweden
Mouse mAB3 a3(IV)NC1 1:40 Wieslab AB, Lund, Sweden
Rat CFT-45325 a2-a5(IV)NC1 1:1 Shigei Medical Research Institute, Okayama, Japan
Mouse mAb A7 a5(IV)NC1 1:4 Wieslab AB, Lund, Sweden
Mouse mAb 5C6 Type VI collagen 1:1000 Hybridoma Bank, Iowa City, IA
Mouse mAb 1924 Laminin a5 1:100 Chemicon International, Temecula, CA
Mouse mAb 1921 Laminin B1(b1) 1:20 Chemicon International, Temecula, CA
Mouse mAb C4 Laminin b2 1:20 Hybridoma Bank, Iowa City, IA
Mouse mAb 1920 Laminin B2 (c1) 1:20 Chemicon International, Temecula, CA
Mouse mAb A9 Nidogen Nidogen/entactin 1:1 Katz et al [33]
Mouse mAb 458 Agrin HSPG 1:100 Chemicon International, Temecula, CA
Mouse mAb 1948 HSPG core protein 1:1000 Chemicon International, Temecula, CA
(Perlecan Domain 4)
Rabbit anti-Fibronectin Fibronectin 1:80 Novotec, Lyon, France
Antibodies
The primary antibodies used in this study, their speci-
ficity, dilution, sources, and references are shown in
Table 2. We previously characterized rabbit polyclonal
P21 and P35 antibodies used for the analysis of podocin
expression [11]. P21 was generated against fusion pro-
teins derived from the whole N-terminal region of the
human protein, before the membrane-associated domain
(amino acids 15 to 89) whereas P35 was made against
the C-terminal region downstream of the membrane-
associated domain (amino acids 135 to 383). By Western
blot analysis of transfected HEK293 cells, both anti-
bodies detected one thick band of 49 kD. They also
immunoprecipitated overexpressed podocin in HEK293-
transfected cells and specifically labeled normal human
and murine podocytes. By immunoelectron microscopy,
both antibodies localized to the podocyte slit diaphragm
area [11]. The polyclonal antinephrin antibody, a gift
from K Tryggvason, was produced against a fusion pro-
tein corresponding to immunoglobulin repeats 1 and 2
of the amino terminal extracellular portion of human
nephrin (amino acids 22 to 240). By Western blot anal-
ysis of extract of isolated normal human glomeruli, it
specifically reacted with one 180 kD band and recog-
nized full-length nephrin in enzyme-linked immunosor-
bent assay (ELISA) as well as in nephrin-transfected
COS-7 cells. It specifically labeled the slit diaphagm of
glomeruli podocytes [32]. Other studies were performed
using commercially available antibodies against other
proteins of the slit diaphragm, CD2AP and ZO-1, adhe-
sion molecules a3-integrin and b-dystroglycan, GLEPP1,
a transmembrane protein tyrosine phosphatase specif-
ically expressed in the podocytes [34], a-actinin and
synaptopodin [35], two actin-associated proteins, and vi-
mentin, an intermediate filament protein expressed by
the podocyte. The specificity of these antibodies has been
established by the firms. Briefly, the rabbit anti-CD2AP
was prepared against a recombinant protein correspond-
ing to the C-terminus (amino acids 350 to 639) of the
human protein. It was shown to give one band in West-
ern blot analysis of CD2AP expression in mouse spleen
extract, and to immunoprecipitate the protein. ZO-1 has
been prepared against a 69 kD fusion protein correspond-
ing to amino acids 4463 to 1109 of human ZO-1 and re-
acts, on Western blots, with human, mouse rat, guinea
pig, and canine ZO-1. In Western blot analysis of the
human colon cancer cell line CACO-2, it specifically re-
acts with the two ZO-1 a+ and ZO-1 a− isoforms. Its
specificity was also confirmed by immunoprecipitation.
CD49c, the monoclonal anti-a3-integrin antibody was
raised against human umbilical vein endothelial cells. It
recognizes an amino-terminal epitope of the integrin-a3
chain and immunoprecipitates the 120 to 130 kD frag-
ment under reducing conditions. In addition, it inhibits
adhesion of human keratinocytes to laminin-5 in vitro
functional assays. The monoclonal anti-b-dystroglycan
antibody has been prepared against 15 of the last 16
amino acids of the C-terminus of the human dystroglycan
948 Zhang et al: Podocin expression in NPHS2 patients
sequence. By Western blot analysis of human skeletal
muscle extract, the antibody detected only one 43 kD
band. The monoclonal anti-GLEPP1 antibody was raised
against GLEPP1 fusion protein. Its specificity was char-
acterized in immunohistochemistry assays. Only the
glomerular epithelium was seen to be positive. No posi-
tivity was detected in other kidney cells or in extrarenal
epithelial cells. The monoclonal antisynaptopodin anti-
body was raised against isolated rat kidney glomeruli. In
Western blot analysis, it reacts with one 100 kD polypep-
tide in brain and 110 kD polypeptide in kidney. It also re-
acts with a 44 kD degradation fragment of synaptopodin.
By immunohistochemistry, it recognizes podocytes and a
subset of telencephalic synapses. The anti-a-actinin poly-
clonal antibody was developed in rabbit using purified
a-actinin from chicken gizzard as an immunogen. It rec-
ognizes the four a-actinin isoforms but it could be used
for this study as only a-actinin-4 is significantly expressed
in the human kidney [29, 31]. The V9 anti-vimentine an-
tibody is a classical one prepared by Osborn, Bebus, and
Weber [36], who established its specificity by Western
blot analysis using porcine vimentin as antigen, or to-
tal cell extract prepared from a human glioma cell line.
Only a single band of molecular weight 57 kD was recog-
nized by the antibody. The antibody was further charac-
terized by immunohistochemical assays [36]. Analysis of
the glomerular extracellular matrix was made using an-
tibodies against types IV and VI collagen, the a1, 2, 3,
and 5 chains of type IV collagen, fibronectin, laminin a5,
b1, b2, and c1 chains, nidogen, perlecan and agrin cya-
nine2 or fluorescein isothiocyanate(FITC)-conjugated
AffiniPure goat or donkey antirabbit IgG and cyanine3-
conjugated AffiniPure donkey antimouse IgG antibodies
were purchased from Jackson ImmunoResearch Labo-
ratories (West Grove, PA, USA). The Vectastain Elite
ABC Kit, avidin-biotin blocking kit, and diaminobenzi-
dine were from Vector Laboratories (Burlingame, CA,
USA).
Immunofluorescence staining
Immunofluorescence labeling was performed on 3 lm
thick cryostat sections fixed in acetone for 10 minutes, and
incubated for 20 minutes with 10% normal swine serum
in phosphate-buffered saline (PBS) containing 0.05%
Tween-20 for blocking nonspecific binding. After incu-
bation for 1 hour at room temperature with primary anti-
bodies diluted in the same buffer, the sections were rinsed
three times in PBS and incubated for 30 minutes with
cyanine2-conjugated antirabbit antibodies diluted 1:100
in PBS, or with cyanine3-conjugated antimouse antibody
diluted 1:500 in PBS. A mounting media for immunoflu-
orescence (Fluoprep) (BioMerieux, Lyon, France) was
used to delay fluorescence quenching. Labeling was ex-
amined with an Orthoplan microscope equipped for
light, fluorescence, and phase contrast microscopy (Leica
Microscopic Systems, Heezbrugg, Switzerland).
Immunoperoxidase
Immunoperoxidase staining, using the Vectastain Elite
ABC Kit (Vector Laboratories), was used for analysis of
expression of GLEPP1 and vimentin. Deparaffinized sec-
tions (4 lm thick) were pretreated by microwave heating
in a urea solution (2 × 5 minutes in 0.8 mol/L urea, pH
6.4). For quenching the endogenous peroxidase, sections
were treated with 3% hydrogen peroxide in methanol for
5 minutes and then washed in PBS for 20 minutes. They
were then incubated for 1 hour at room temperature in
a moist chamber with anti-GLEPP1 or anti-vimentin an-
tibody. After washing in PBS, they were incubated with
biotinylated secondary antibodies for 30 minutes. They
were then incubated for 30 minutes with Vectastain Elite
ABC reagent. Chromogen was diaminobenzidine. No la-




For dual fluorochrome labeling, the slides were
simultaneously incubated with mouse anti-nidogen
antibodies and rabbit anti-podocin, anti-nephrin,
anti-CD2AP or anti-a-actinin antibodies. After washing
with PBS, the slides were simultaneously incubated
with cyanine2-conjugated donkey antirabbit IgG and
cyanine3-conjugated donkey antimouse IgG. Sections
were examined with an Orthoplan microscope equipped
with appropriate filters (Leica Microscopic Systems) and
with a Zeiss confocal microscope (Carl Zeiss Microscopy,
Jena, Germany).
NPHS2 in situ hybridization
In situ hybridization was carried out on paraffin-
embedded sections according to a standard protocol pre-
viously reported [2, 11]. Paraffin-embedded 6 lm thick
sections were deparaffinized, rehydrated, and treated by
microwave heating in sodium citrate buffer (0.01 mol/L,
pH 6.0). The NPHS2 riboprobes were synthesized from a
1065 bp polymerase chain reaction (PCR) product (span-
ing bases 728 to 1792 in the NPHS2 cDNA) subcloned
into the vector PGEM-Teasy (Promega, Madison, WI,
USA). The antisense probe was synthesized after diges-
tion with SalI using T7 RNA polymerase and sense probe
after digestion with SacII using Sp6 RNA polymerase.
The riboprobes were labeled with digoxigenin (DIG)-
11-uridine triphosphate (UTP) (Roche Diagnostics,
Penzberg, Germany) and subsequently visualized using
anti-DIG antibody fragments coupled with alkaline phos-
phatase. The specificity of this probe has been previously
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Fig. 1. In situ hybridization of antisense and
sense NPHS2 riboprobe labeled with digoxi-
genin. In normal kidney, strong signals were
observed in podocytes, at the periphery of the
glomerular tuft (A). No specific signals were
observed with the sense probe (B). Faint label-
ing was seen in the patient with homozygous
nt 417delG mutation (C). In contrast, there
were no significant changes in the intensity of
podocin mRNA labeling in the other patients
(D) (magnification × 300).
established by northern blot analysis and in situ hy-
bridization of normal fetal and adult kidneys [2].
RESULTS
Podocyte expression of podocin
In situ hybridization. In normal kidneys, as previously
shown [2, 11] strong podocin expression of the transcripts
was seen in podocytes, at the periphery of the glomeru-
lar tuft (Fig. 1A) and no signal was observed with the
sense probe (Fig. 1B). In patient 2, with the homozy-
gous 419delG mutation, faint labeling was seen in the
podocytes (Fig. 1C). In contrast, there was no significant
changes in the intensity of podocin mRNA labeling in the
other patients (Fig. 1D).
Podocin distribution. In normal kidneys, polyclonal
antibodies against the C- or the N-terminal regions of
podocin gave the same pattern of immunolabeling but the
staining was stronger with the anti-C terminal antibodies
that could be used at a higher dilution. Both antibodies
gave a precise staining of the basal region of the podocyte
along the GBM (Fig. 2A and B) [11].
In NPHS2 patients, the pattern of podocin expres-
sion varied according to the type of NPHS2 mutation.
In two patients with homozygous 855 8566delAA or
419delG frameshift mutation leading to the synthesis
of a truncated protein, podocyte expression of the N-
terminal domain of the podocin contrasted with the
absence of labeling with the antibodies against the C-
terminal domain (Fig. 2C and D). The expression of the
N-terminal domain was strong in the patient with ho-
mozygous 855 856delAA, and reduced in the other one.
In both of them podocyte labeling was precisely located
along the GBM. In patients 3 to 6 carrying different types
of point mutations (R168S/467 468insT, R138Q/V180M,
R291W/R229Q, and 976 977insA), podocin expression
was observed with both antibodies but the distribution
of the protein was modified. Podocin was clearly re-
stricted to the podocyte body in the patient carrying the
R168S/467 468insT mutation (Fig. 2E) whereas immuno-
labeling of the podocyte body was associated with label-
ing along the GBM in the three others (Fig. 2F).
Double immunofluoresence labeling and confocal mi-
croscopy. In normal kidneys, double immunofluores-
cence labeling of podocin (in green) and nidogen, a
component of the GBM (in red) showed a nearly com-
plete overlap of the red and green stainings (Fig. 3A).
However, high magnification and confocal microscopy
examination focally disclosed the red nidogen labeling
restricted to the GBM, from the green podocin labeling
at the basis of the podocytes. In patients 1 and 2, the
pattern of labeling with the anti-N-terminal domain of
podocin was similar to the one in controls (Fig. 3B). In
patient 3 with the R168S/467 468insT mutation, dual im-
munolabeling clearly confirmed the selective labeling of
the podocyte body with antipodocin antibodies (Fig. 3C),
whereas more diffuse distribution, in the podocyte body
and along the GBM was observed in patients 4 to 6. The
nidogen expression was unchanged.
Expression of other podocyte-specific protein
Immunofluorescence/immunoperoxydase labelings.
In normal kidneys, the glomerular distribution of
slit diaphragm-associated proteins nephrin, CD2AP
and ZO-1, of the adhesion molecules a3-integrin and
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Fig. 2. Immunostaining of podocin in
glomeruli from controls and patients carrying
NPHS2 mutations. In normal kidneys,
polyclonal antibodies against the N- or
the C-terminal regions of podocin gave a
precise staining of the basal region of the
podocyte along the glomerular basement
membrane (GBM) (A and B). In patients
with homozygous 855 856delAA or 417delG
frameshift mutation, podocyte expression of
the N-terminal domain of the podocin (C)
was observed whereas no labeling with the
antibodies against the C-terminal domain
(D) could be detected. Podocyte labeling of
podocin N-terminal domain was precisely
located along the GBM (C). Podocin was
clearly restricted to the podocyte body in
the patient carrying the R168S/467 468insT
mutation (E) whereas prominent immunola-
beling of the podocyte body was associated
with segmental labeling along the GBM
in the three other ones carrying mutations
of R138Q/V180M, R291W/R229Q, and
976 977insA (F) [magnification (A, B, and F)
× 300; (C and D) × 250; (E) × 200].
b-dystroglycan, and the other podocyte proteins a-
actinin, GLEPP1, and synaptopodin appeared to be
similar to that of podocin, by immunofluorescence/
immunoperoxidase microscopy. CD2AP and a-actinin
were seen in the podocyte along the capillary wall, with
focal enhancements toward the podocyte body. ZO-1,
a-actinin, and CD2AP were also expressed in tubular
cells, and ZO-1 in the glomerular parietal epithelial.
Strong labeling of podocyte cytoplasm was observed
with anti-vimentin antibodies.
In the six NPHS2 patients, changes in the distribution
of nephrin, CD2AP, and a-actinin were observed. In all
of them, nephrin was detected not only along the GBM
with a granular and discontinuous distribution, but also
in the podocyte body. Labeling of CD2AP and a-actinin
was markedly increased and frequently seen in the entire
podocyte. No significant changes in the glomerular dis-
tribution of other podocyte proteins were detected in the
NPHS2 patients.
Double immunofluoresence labeling and confocal mi-
croscopy. To precisely delineate the changes in the
distribution of slit diaphragm proteins we have just
mentioned, dual labelings were performed with antibod-
ies against nephrin, CD2AP or a-actinin (in green) and
nidogen, a GBM marker (in red) and examined by confo-
cal microscopy (Fig. 3). In normal kidneys, partial overlap
of dual labeling resulted in a yellow linear staining of the
GBM associated with a green labeling following the ex-
ternal aspect of the basement membrane (Fig. 3D, G, and
J). In patients with NPHS2 mutations, the green labeling
of the podocyte body was strong with all three antibodies
contrasting clearly with the red GBM labeling (Fig. 3E,
F, H, I, K, and L). Focal superposition of labelings was
revealed by the segmental yellow staining of the GBM.
Glomerular expression of extracellular matrix proteins
Because of the possible consequences of NPHS2 mu-
tation on the podocyte synthesis of extracellular proteins,
we analyzed the distribution of glomerular extracellular
matrix components. No difference in their pattern of dis-
tribution was detected between normal and NPHS2 pa-
tient kidneys. Antibodies to the a1 and a2 chains of type
IV collagen or to [a1(IV)2a2(IV)]-labeled the mesan-
gial matrix and gave a thin linear staining of the GBM
whereas antibodies to the a3 to a5 (IV) chains strongly
stained the GBM.
Antibodies to type VI collagen and fibronectin stained
the mesangial matrix and faintly labeled the subendothe-
lial aspect of the GBM. Antibodies against nidogen, and
laminin chains a1/a5, b2, and c1 gave a linear staining





Fig. 3. Double immunofluorescence and confocal microscopy with polyclonal antibodies against podocin (A to C), nephrin (D to F), CD2-associated
protein (CD2AP) (G to I), or a-actinin (J to L) (in green) and monoclonal anti-nidogen (in red). In normal glomeruli, partial overlap of the red
and green labelings results in a yellow linear staining of the glomerular basement membrane (GBM) (A, D, G, and I). In patients 1 and 2 with
truncating mutation, the pattern of labeling with the anti N-terminal domain of podocin was similar to the one in controls (B). In patients 3 to 6
with other types of mutation, dual immunolabeling clearly confirmed the diffuse cytoplasmic labeling of the podocytes with antipodocin antibodies
(C). In all patients, whatever the type of NPHS2 mutations, green labeling was strong in the podocyte body with antinephrin, CD2AP, and a-actinin
antibodies contrasting clearly with the red GBM labeling (E, F, H, I, K, and L). Focal superposition of labelings was revealed by the segmental
yellow staining of the GBM (magnification × 200).
of the GBM, whereas b1 chain labeling was faint and
restricted to the mesangial matrix. Anti-agrin antibodies
gave a strong linear staining of the GBM, whereas an-
tiperlecan antibodies stained the mesangial matrix (data
not shown).
DISCUSSION
Podocytes are highly specialized cells located on the
external side of the glomerular capillary walls. Their
voluminous cell body that protrudes into the urinary
space emits thick extensions that divide into pedicels or
foot processes and attach to the GBM. Adjacent foot
processes, derived from different podocytes, are joined
laterally by a thin structure, the slit diaphragm, now re-
garded the major glomerular size-selective filter [24, 37,
38]. Podocin normally localizes at the insertion site of the
slit diaphragm, in lipid rafts, specialized microdomains
of the plasma membrane involved in cell signaling pro-
cesses, and signal transduction pathways [9]. It interacts
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with nephrin, CD2AP, and NEPH proteins through its
C-terminal cytoplasmic domain and those interactions
facilite nephrin signaling [9, 19, 39–41]. Within the foot
processes, a contractile cytoskeleton, composed of actin,
myosin II, a-actinin-4, talin, and vinculin [42] is linked to
the slit diaphragm, and connected to the foot processes’
soles and the underlying GBM through the a3b 1 integrin
and the dystroglycan complexes. Mutations in NPHS2 en-
coding podocin, result in severe glomerular disease char-
acterized by early onset proteinuria/nephrotic syndrome
with effacement of podocyte foot processes, steroid re-
sistance and progression to ESRD [2–7, 10, 43, 44]. No
slit diaphragm was observed in glomeruli of Nphs2−/−
mice examined from the age of 16.5 embryonic days on-
ward, at a stage when podocytes of mature glomeruli in
the deep cortex are fully differentiated in normal con-
trol animals [10]. The severe clinical and morphologic
consequences of the absence or structural alteration of
podocin prompted us to examine the expression pattern
of podocin and slit diaphragm-associated proteins in a se-
ries of renal biopsies from nephrotic patients with NPHS2
mutations. We enlarged this study to the analysis of sev-
eral other podocyte proteins and glomerular extracellular
matrix components.
In normal kidneys, by immunofluorescence or im-
munoperoxidase stainings, podocin, nephrin, CD2AP,
and a-actinin-4 appear to be codistributed, along the
outer surface of the GBM. This labeling is correlated with
the foot process distribution of the proteins. In NPHS2
patients, the pattern of podocin expression varied accord-
ing to the type and location of the mutation. Two patients
had homozygous deletions of 1 or 2 bp predicted to in-
troduce a frameshift and to lead to the production of a
truncated protein. In the first one, with mutation located
in exon 7 resulting in the absence of the last 98 amino
acids of the protein, no important change in RNA expres-
sion was detected by in situ hybridization. As expected,
no staining of the C-terminal domain was observed. In
contrast, a strong podocyte labeling of the N-terminal
domain was seen along the GBM, indicating a normal lo-
calization of the truncated protein. Changes were similar
in the second patient with frameshift mutation in exon
3 leading to the truncation of 203 amino acids, but the
expression of the transcripts and the podocin N-terminal
domain was strikingly reduced, a possible consequence
of rapid RNA decay and/or degradation of the truncated
protein. Along the same lines, as previously reported in a
patient with a homozygous nonsense mutation in exon 3,
very low RNA expression was detected by reverse tran-
scription (RT)-PCR [2] and no protein was seen by im-
munofluorescence [11]. In the three patients with com-
pound point mutations, the expression of NPHS2 tran-
scripts seemed normal but the protein distribution was
severely modified. It was restricted to the podocyte body,
without any visible labeling of the basis of the cell along
the GBM, in the patient with the compound heterozy-
gous mutation R168S/467 468insT. Recently, Roselli
et al [45] have shown that the R168S mutant podocin
is retained in the endoplasmic reticulum in vitro. Our
results strongly suggest that the same defect in intracel-
lular trafficking occurs in vivo in the podocytes of this
patient. In patients carrying mutations R138Q/V180M or
R291W/R229Q, strong podocin labeling of the podocyte
body was associated with moderate labeling along the
GBM. Interestingly, in opossum kidney (OK) cells, hu-
man podocytes and embryonic kidney cells, the R138Q
podocin mutant was shown to be also retained in the en-
doplasmic reticulum [45, 46]. Moreover, the R291W mu-
tant accumulated in late endosomes, whereas the V180
mutant and the R229Q variant were normally targeted
to the plasma membrane [45]. Here, our findings suggest
that the same processus occurs in vivo in patients with
compound missense mutations, resulting in the presence
of podocin in the podocyte body and along the GBM.
In the patient in which a single heterozygous frameshift
mutation has been identified, the expression of the tran-
script appeared to be normal but podocin was present
in the podocyte body and along the GBM, suggesting a
normal expression of the normal allele.
In all NPHS2 patients, the podocin defect resulted in
major changes in the podocyte location of nephrin and
CD2AP characterized by switching from a podocyte lo-
calization along the GBM in controls to a prominent lo-
cation in the podocyte body in patients. Podocin, nephrin,
and CD2AP have been shown to co-localize and interact
within lipid raft domains of the plasma membrane facing
the filtration slit [9]. More recently, it was demonstrated,
by in vitro experiments, that podocin recruits nephrin in
lipid rafts, and that recruitment is abolished in the ab-
sence of podocin, or the presence of mutated proteins
retained in the endoplasmic reticulum or not targeted to
rafts [47]. Our morphologic findings in vivo are consis-
tent with these data: protein interactions demonstrated
in vitro likely explain the mislocalization of nephrin
and CD2AP observed in patients with mutated podocin.
Interestingly, similar changes in nephrin expression,
characterized by strong labeling of the podocyte body, as-
sociated with increased CD2AP podocyte labeling, were
observed in Nphs2−/− mice [10]. The distribution of a-
actinin-4, a component of the contractile apparatus of the
podocyte foot processes, was also modified in the patients.
In contrast to the normal distribution along the GBM, a-
actinin was also seen in the podocyte body, a possible
consequence of the disruption of the slit diaphragm com-
plex that is normally anchored to the actin cytoskeleton,
possibly by linkage to CD2AP [48, 49]. Using a human
podocyte cell line, Saleem et al [50] provided functional
evidence for an intimate relationship between the actin
cytoskeleton and the slit diaphram proteins by showing
that normal intra cellular co-localization of these proteins
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is dependent on intact actin polymers. All of these find-
ings are additional evidences of the tight interdependence
of proteins participating in the formation of the foot pro-
cess cytoskeleton and slit diaphragm structure. ZO-1 is
known to be co-localized with nephrin in glomeruli, from
the S-shaped body stage, and to concentrate in the slit di-
aphragm of mature glomeruli [51]. It also interacts with
Neph family members and could contribute to the orga-
nization of the filtration slit [52]. However, normal ex-
pression of ZO-1 along the GBM was observed in the
6 patients with NPHS2 mutation and disrupted localiza-
tion of other slit diaphragm-associated proteins. A nor-
mal expression of ZO-1 has also been found in the kidneys
of nephrin null mice [53] and NPHS1 fetuses with Fin-
major/Finmajor genotype, who completely lack nephrin
and slit diaphragm [51]. These findings suggest that ZO-
1 does not belong to the same multimolecular complex
participating in the formation of slit diaphragm than
nephrin/podocin/CD2AP. No changes were detected in
the distribution of the adhesion molecules a3-integrin
and b-dystroglycan, implicated in the attachment of the
sole of the foot processes to the GBM, the transmem-
brane protein tyrosine phosphatase GLEPP1, the actin-
associated protein synaptopodin, or the intermediary
filament vimentin. In the same way, no changes were ob-
served in the composition or the distribution of glomeru-
lar extracellular matrix components, a finding consistent
with the absence of specific ultrastructural abnormalities
of the GBM.
CONCLUSION
Most NPHS2 mutations result in profound alteration
of podocin expression and/or distribution, from normal
location of truncated proteins lacking the C-terminal
domain, to mislocalization of the mutated protein in
the podocyte body. Podocin is normally targeted to the
plasma membrane via the classical endoplasic reticulum
pathway [45]. It may be suggested that, in vivo as shown
in in vitro experiments, some NPHS2 missense mutations
prevent correct folding of the protein which is retained in
the endoplasmic reticulum or internalized [45, 46]. Sec-
ondary changes in the distribution of nephrin and CD2AP
are additional evidences of the scaffolding role of podocin
in the organization of the slit diaphragm.
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